June 7, 2022 |
VBI Vaccines Reports Full Year 2022 Financial Results
VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
VBI Vaccines Announces Health Canada Approval for PreHevbrioâ„¢ for the Prevention of Hepatitis B in Adults